0
settings
الوضع الليلي
moon
انماط الصفحة الرئيسية arrow
EN
1
المرجع الالكتروني للمعلوماتية

النبات

مواضيع عامة في علم النبات

الجذور - السيقان - الأوراق

النباتات الوعائية واللاوعائية

البذور (مغطاة البذور - عاريات البذور)

الطحالب

النباتات الطبية

الحيوان

مواضيع عامة في علم الحيوان

علم التشريح

التنوع الإحيائي

البايلوجيا الخلوية

الأحياء المجهرية

البكتيريا

الفطريات

الطفيليات

الفايروسات

علم الأمراض

الاورام

الامراض الوراثية

الامراض المناعية

الامراض المدارية

اضطرابات الدورة الدموية

مواضيع عامة في علم الامراض

الحشرات

التقانة الإحيائية

مواضيع عامة في التقانة الإحيائية

التقنية الحيوية المكروبية

التقنية الحيوية والميكروبات

الفعاليات الحيوية

وراثة الاحياء المجهرية

تصنيف الاحياء المجهرية

الاحياء المجهرية في الطبيعة

أيض الاجهاد

التقنية الحيوية والبيئة

التقنية الحيوية والطب

التقنية الحيوية والزراعة

التقنية الحيوية والصناعة

التقنية الحيوية والطاقة

البحار والطحالب الصغيرة

عزل البروتين

هندسة الجينات

التقنية الحياتية النانوية

مفاهيم التقنية الحيوية النانوية

التراكيب النانوية والمجاهر المستخدمة في رؤيتها

تصنيع وتخليق المواد النانوية

تطبيقات التقنية النانوية والحيوية النانوية

الرقائق والمتحسسات الحيوية

المصفوفات المجهرية وحاسوب الدنا

اللقاحات

البيئة والتلوث

علم الأجنة

اعضاء التكاثر وتشكل الاعراس

الاخصاب

التشطر

العصيبة وتشكل الجسيدات

تشكل اللواحق الجنينية

تكون المعيدة وظهور الطبقات الجنينية

مقدمة لعلم الاجنة

الأحياء الجزيئي

مواضيع عامة في الاحياء الجزيئي

علم وظائف الأعضاء

الغدد

مواضيع عامة في الغدد

الغدد الصم و هرموناتها

الجسم تحت السريري

الغدة النخامية

الغدة الكظرية

الغدة التناسلية

الغدة الدرقية والجار الدرقية

الغدة البنكرياسية

الغدة الصنوبرية

مواضيع عامة في علم وظائف الاعضاء

الخلية الحيوانية

الجهاز العصبي

أعضاء الحس

الجهاز العضلي

السوائل الجسمية

الجهاز الدوري والليمف

الجهاز التنفسي

الجهاز الهضمي

الجهاز البولي

المضادات الميكروبية

مواضيع عامة في المضادات الميكروبية

مضادات البكتيريا

مضادات الفطريات

مضادات الطفيليات

مضادات الفايروسات

علم الخلية

الوراثة

الأحياء العامة

المناعة

التحليلات المرضية

الكيمياء الحيوية

مواضيع متنوعة أخرى

الانزيمات

قم بتسجيل الدخول اولاً لكي يتسنى لك الاعجاب والتعليق.

Genetic Basis of Acute Lymphoblastic Leukemia: KMT2A Fusion Genes

المؤلف:  Hoffman, R., Benz, E. J., Silberstein, L. E., Heslop, H., Weitz, J., & Salama, M. E.

المصدر:  Hematology : Basic Principles and Practice

الجزء والصفحة:  8th E , P1054-1055

2026-11-19

25

+

-

20

Translocations involving the KMT2A gene (previously known as MLL) on chromosome 11q23 occur in approximately 80% of infant ALL cases, 5% of AML cases, and 85% of secondary AML cases that occur in patients treated with topoisomerase II inhibitors. KMT2A is the human ortholog of the Drosophila trithorax gene. Trithorax proteins are positive regulators of homeobox gene expression and act antagonistically to polycomb proteins. WT KMT2A positively regulates HOX gene expression and is required for both primitive and definitive hematopoiesis. WT KMT2A is a member of a large transcriptional regulatory complex, together with histone deacetylases and members of the SWI/SNF chromatin-remodeling complex.

The KMT2A protein undergoes proteolytic processing by Taspase1, a specialized protease that cleaves the KMT2A protein into N-terminal (KMT2AN) and C-terminal (KMT2AC) fragments that remain asso ciated through intramolecular protein–protein interaction domains. KMT2AN contains several DNA-binding domains, including AT-hook domains that nonspecifically bind the minor groove of DNA, a meth yltransferase homology region (CxxC domain) that specifically binds unmethylated DNA, four plant homeodomain zinc fingers with an embedded bromodomain, and a transcriptional repression domain. The C-terminal fragment KMT2AC contains a transcriptional activation domain that recruits the histone acetyltransferase cAMP response element-binding protein (CBP) and a SET domain that is responsible for its histone 3 lysine 4 (H3K4) methyltransferase activity.

WT KMT2A encodes an H3K4 lysine methyltransferase, and H3K4 methylation is associated with transcriptional activation. KMT2A fusion oncogenes result from translocations whose break points cluster between exons 5 and 11 of KMT2A, and the resultant fusion proteins retain the N-terminal region of KMT2A, including the AT-hook and CxxC domains that bind DNA in a sequence-non specific manner. By contrast, the C-terminal domains that mediate the association of WT KMT2A with its endogenous chromatin remodeling complex and its H3K4 methyltransferase activity are invariably lost from oncogenic KMT2A fusion proteins. Instead, the C-terminus of KMT2A fusion proteins is provided by one of more than 60 different translocation partners, with common translocations such as the t(4;11), t(9;11), and t(11;19)(q23;p13.3) resulting in the in-frame fusion of KMT2A to AF4, AF9, and ENL, respectively. The unrelated t(11;19)(q23;p13.1) translocation results in the fusion of KMT2A to ELL, the RNA polymerase II elongation factor.

Formal proof that KMT2A fusions play a critical role in the development of leukemias has come from the generation of murine models of KMT2A-induced leukemias. Chimeric mice harboring a KMT2A AF9 fusion gene generated by homologous recombination developed leukemias with a latency of 4 to 12 months. Retroviral transduction of KMT2A–ENL, KMT2A–ELL, and KMT2A–CBP fusion genes in hematopoietic precursors induces transformation upon transplantation into recipient mice. Similar results were obtained with a model in which chromosomal translocations involving the KMT2A locus are induced by directed interchromosomal recombination in mice, a strategy that reproduces experimentally the initiating events in the pathogenesis of KMT2A-rearranged leukemias. Interestingly, the introduction of KMT2A–AF9 into committed granulocyte-macro phage progenitors in the mouse leads to the reactivation of a subset of genes normally expressed only in HSCs and transforms these com mitted precursors into AML leukemic stem cells by imparting the properties of self-renewal, suggesting that the leukemogenic lesion in KMT2A-rearranged leukemia might occur in a committed progenitor rather than in a pluripotent HSC.

KMT2A-rearranged B-lineage leukemias have a characteristic gene expression signature that includes the upregulation of several HOX genes and the expression of numerous myeloid markers. Both early B- and T-cell ALLs with KMT2A rearrangements showed a characteristic upregulation of specific HOX genes, including HOXA9, HOXA10, and HOXC6, and the HOX gene regulator MEIS1. These results, together with the demonstration that HOXA9 plays important roles in the transformation of hematopoietic precursors by KMT2A fusion oncogenes in murine leukemia models, emphasize the central role of HOX gene dysregulation in the pathogenesis of KMT2A-rearranged leukemias. Additionally, as discussed later in this chapter, overexpression or activating mutations of the FLT3 receptor tyrosine kinase (RTK) are frequent in KMT2A-rearranged leukemias.

Until recently, the precise mechanisms mediating the oncogenic activity of KMT2A fusion proteins were unclear because KMT2A translocation partners have no sequence similarity. However, recent work has shown that several distinct KMT2A translocation partners are functionally linked through their association in protein complexes that regulate transcriptional elongation. Oncogenic KMT2A-fusion proteins have been implicated in the DOT1L, SEC, and PAFc transcriptional complexes. The DOT1L complex consists of DOT1L, a histone H3 lysine 79 (H3K79) methyltransferase, and multiple KMT2A fusion partners, including AF9, ENL, and AF10. The SEC (also known as p-TEFb or AEP) complex consists of a CDK9 and cyclin T heterodimer (known as p-TEFb) that phosphorylates RNA polymerase II, interacts with several KMT2A fusion partners, including ENL, ELL, AF4, and AF5, and co-purifies with several KMT2A fusion proteins. PAFc, the polymerase-associated factor complex, regulates RNA polymerase II and associates with the amino terminus of both WT KMT2A and KMT2A fusions.

The observation that DOT1L interacts with multiple KMT2A translocation partners suggests that KMT2A fusion proteins may drive ectopic gene expression through recruiting excessive DOT1L activity to their target loci. DOT1L encodes a histone H3K79 methyltransferase, and many of the target genes directly upregulated by oncogenic KMT2A fusions are characterized by aberrant H3 lysine 27 (H3K27) methylation, including the 5′ HOXA cluster genes and MEIS1. Interestingly, the DOT1L methyltransferase is required for the transformation of murine bone marrow progenitors by KMT2A fusion oncoproteins, but it plays a less prominent role in normal hematopoiesis.

The oncogenic activity of KMT2A fusions also requires their physical interaction with Menin, the tumor suppressor protein encoded by the multiple endocrine neoplasia 1 (MEN1) gene. Menin binds an N-terminal domain of KMT2A that is conserved in all KMT2A fusion proteins. Moreover, abrogating the interaction of Menin with KMT2A, either by deleting Menin or by mutating the Menin-binding domain of KMT2A, impairs both transcriptional and oncogenic functions of KMT2A fusions. These findings spurred the development of small-molecule inhibitors of the KMT2A-menin interaction. Studies of small molecular inhibitors have provided critical insight into the mechanism by which KMT2A-Menin inhibition acts through the displacement of KMT2A chromatin occupancy at select target genes (Fig. 1) and have demonstrated promising activity in preclinical models, both in vitro and in vivo, including complete eradication of leukemia in a patient-derived xenograft model of KMT2A-rearranged acute leukemia, providing the rationale for early phase clinical trials of Menin inhibitors in relapsed/refractory KMT2A-rearranged acute leukemias.

Fig1. MODEL FOR THE CONSEQUENCES OF DOT1L VERSUS MENIN INHIBITION FOR THE INTEGRITY OF THE MLL-AF9 COMPLEX ON CHROMATIN. At steady state, the intact MLL-AF9 complex stably binds to its target genes via Menin and recruits the DOT1L complex to drive histone H3 lysine 79 methylation (H3K79me2) and gene expression of canonical target genes (e.g., MEIS1) (left). DOT1L inhibition removes H3K79me2 by blocking the enzymatic activity of the methyltransferase while leaving the complex largely intact (middle). Inhibition of the Menin-MLL interaction disrupts the integrity of the MLL-AF9 complex, leading to a more rapid and profound response (right). (Adapted from Perner F, Armstrong SA. Targeting chromatin complexes in myeloid malignancies and beyond: from basic mechanisms to clinical innovation. Cells. 2020;9:2721, with permission).

The presence of KMT2A rearrangements is associated with inferior outcomes despite aggressive chemotherapy, especially in infants with ALL, 80% of whom present with KMT2A-rearrangements.

اخر الاخبار

اشترك بقناتنا على التلجرام ليصلك كل ما هو جديد